TKMR: ARTICLE BY
KarinCA
Long only, biotech, small-cap, micro-cap
Profile| Send Message| Follow (328 followers)
Tekmira Pharmaceuticals Is More Than Just A Short-Term Ebola Trade
Aug. 27, 2014 3:12 PM ET | About: Tekmira Pharmaceuticals Corp (TKMR), Includes: BCRX, CMRX, FUJIY, GSK, IMMVF, INO, NLNK, PPHM, SIGA, SRPT
Disclosure: The author is long TKMR. (More...)
Summary
Ebola has thrust a virtually unknown company into the spotlight. Unknown to average retail investors, but, not unknown in its industry, Tekmira has some interesting technology and partners.
The pipeline may turn this into a longer-term hold once the volatility subsides.
TKM-Ebola and why it’s currently ahead of the competition.
Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) is located in Vancouver Canada and is a world leader in RNA interference, RNAi. Description of RNAi from the TKMR website:
"RNAi has the potential to generate a new class of therapies to take advantage of the body's own natural processes to silence genes and, by extension, treat serious human diseases that often rely on the production of certain proteins at the genetic level. This method of treatment is not currently available with conventional drugs."Tekmira Pharmaceuticals Corp. is located in Vancouver Canada and is a world leader in RNA interference, RNAi. Description of RNAi from the TKMR website:
This potentially enables the generation of a new and safer class of medications.
Their LNP Delivery Platform gives them a way to successfully deliver and enable the RNAi drugs.
"LNPs are designed to stay in the circulation long enough to accumulate at disease sites, such as the liver or cancerous tumors. Through a process called endocytosis, cells take up the LNPs which allows them to migrate into the cell. The LNPs then undergo an interaction within the cell and the siRNA drug is released, mediating RNAi."
The most recent annual report, Form 10-K was filed 3.28.14. They had 92 employees at the time of that filing. Most of them are in research and development. They also have three wholly owned subsidiaries. (Protiva Biotherapeutics Inc., Protiva Agricultural Development Company Inc. and Protiva Biotherapeutics U.S.A. Inc.).
Collaborators and partners since inception include Alnylam Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Takeda Pharmaceutical Company, the US government's Transformational Medical Technologies program, aka TMT, Monsanto, and others.
The current outbreak of Ebola is the worst case since it first showed up in 1976 and has thrust the company in the news almost daily. This in turn, has caused volatile trading of the stock.
page 1 / 2|Next »
News 
Market Data 
Discover 
